Study details
Enrolling now
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AbbVie
NCT IDNCT06524635ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 2.5 years
Ages
18–75
Locations
2 sites in CA, MI
What this study is about
This trial is testing a treatment called lutikizumab for people with hidradenitis suppurativa (HS) or atopic dermatitis (AD). Participants will receive subcutaneous injections of lutikizumab and have regular visits, blood tests, and biomarker collections. It duration is expected to last up to 30 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lutikizumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
subcutaneous
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
monoclonal antibody
Drug routes
subcutaneous
Endpoints
Primary: Number of Participants With Adverse Events (AEs)
Body systems
Dermatology